Bellerophon Therapeutics (BLPH) shares have surged in early trading today after the company announced hat Belgian health authorities have approved the commencement of an open-label Phase 2 study assessing INOpulse for the treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease (PH-COPD). Patient recruiting (10 total) will start this quarter with results expected by year end.